Pelosi plan to lower drug prices faces political challenges

Amy Baxter | | Health Exec | Policy & Regulations

House Speaker Nancy Pelosi’s (D-CA) bill to lower drug prices is facing new challenges as congressional Democrats debate changes to the plan, The Hill reported.

Centrist Democrats are warning leadership that if the plan moves further to the left, it could start to lose support and votes. Others are pushing for stronger reforms to “toughen up” the legislation.

“Pelosi will have to thread the needle between these dueling factions as she plans to bring the measure to the floor as soon as mid-November,” the report reads.

Pelosi introduced the plan in September, calling the bill The Lower Drug Costs Now Act. The plan enables the HHS to negotiate lower prices for hundreds of Medicare drugs––something currently prohibited under law.

See the full story below:

House Democrats clash over Pelosi's drug pricing bill

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

OCR investigating Michigan health system over possible violation of 'Church Amendments'
PHOTO GALLERY: AMA House of Delegates meeting
Papers discussing ‘gender’ have been restored to government website
AMA agrees to help after initial request for an independent cardiovascular board was denied
AMA president warns prior authorization hurting patients, driving burnout and practice closures
Veterans Affairs denies it discriminates based on politics, marital status

Around the web

Cardiovascular Business
AMA agrees to help after initial request for an independent cardiovascular board was denied

After their proposal for a new American Board of Cardiovascular Medicine was shot down earlier this year, cardiology groups have asked the AMA for some support. "We feel like it's time for us to blaze our own path," one specialist explained. 

Cardiovascular Business
Eli Lilly to acquire gene-editing specialists focused on CVD for up to $1.3B

The company has agreed to acquire Verve Therapeutics for an upfront payment of approximately $1 billion. The total could increase significantly, however, if certain milestones are met. One of Verve's biggest gene therapies has already received the FDA's fast track designation.

Cardiovascular Business
AMA House of Delegates helps cardiology groups influence healthcare policies

American College of Cardiology Board of Governors Chair David E. Winchester, MD, MS, examines the many benefits of working with the American Medical Association House of Delegates to bring about significant change.